Malignant effusions and immunogenic tumour-derived exosomes.

By F. André, N. Schartz, Mojgan Movassagh, C. Flament, P. Pautier, P. Morice, C. Pomel, C. Lhommé, B. Escudier, Thierry Le Chevalier and 5 more. The Lancet, 2002

944 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/5fc3b8dcdfac518c4c32185cb8d1208effec8966

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Molecular Biology

Citations in the corpus

The regulation of exosome secretion: a novel function of the p53 protein. (2006, background): “Exosomes isolated from the malignant effusions (ascites) of patients with cancer contain antigens specific to the tumor, including Her2/Neu from ovarian cancer ascites, and Mart1 from patients with melanoma (43).”
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper (2015, positive): “duced anti-tumour immune responses in mice (26,27).”
Exosome-Based Cell-Cell Communication in the Tumor Microenvironment (2018, background): “In fact, early reports showed that antigens in tumor-derived exosomes can be transferred to DCs and induce specific anti-tumor immune responses (Andre et al., 2002; Robbins and Morelli, 2014).”
Exosomes and their roles in immune regulation and cancer. (2015, background): “[88] Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, et al.”
Body fluid derived exosomes as a novel template for clinical diagnostics (2011, background): “Exosomes are membrane vesicles with a size of 40-100 nm that are released from many different cell types in the body such as red blood cells, platelets, lymphocytes, dendritric cells and also tumor cells [ 1-3 ].”
Tetraspanins in Extracellular Vesicle Formation and Function (2014, background): “Early studies showed that immune cells such as T lymphocytes, B cells, and DCs are able to release EVs, and those EVs secreted by APCs were also able to present MHC–peptide complexes to specific T cells inducing an adaptive immune response (120–122).”
The emerging role of lysophosphatidic acid in cancer (2003, background): “sPLA2 selectively hydrolyses lipids that are present in damaged membranes, membranes of activated cells, or microvesicles such as those released during apoptosis or that are produced by cancer cell”
MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. (2008, background): “Although exosome release can be demonstrated in many proliferating cell types, their release is exacerbated in tumor cells, as evidenced by their elevated presence in plasma, ascites and pleural effusions of cancer patients [26,27].”
Exosomes: a common pathway for a specialized function. (2006, background): “In addition there is increasing evidence for the presence of exosomes in physiological fluids such as plasma (14), malignant and pleural effusions (15, 16) and urine (17).”
High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients (2009, background): “Although exosomes are implicated in a vast array of cellular functions, and have been considered a cell-free source of tumor antigens when secreted by cancer cells [11,18], they have been lately hypothesized to foster immunosuppression in tumorbearing hosts [3,9,12,16,30].”